News
-
-
Kriya Appoints Katherine Eade as Chief Legal Officer
-
Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
-
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
-
Kriya Announces Gene Therapy Program for Thyroid Eye Disease
-
Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference
-
Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
-
Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases
-
Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases